This study is for people with advanced melanoma (a type of skin cancer) that can't be removed by surgery or is stage IV. The study looks at how well two drugs, ipilimumab and nivolumab, work when given at different times of the day. These drugs help the body's defense system fight the tumor. Some patients benefit from them, but many do not. Scientists want to see if giving these drugs in the morning helps more people.

• This study lasts up to 2 years, with regular follow-ups for up to 5 years.
• Patients must visit every 3 weeks for drug cycles and have various tests like blood samples and scans.
• Participation is for adults (18+) with specific types of melanoma.

During the study, patients will be split into three groups, each getting the drugs at different times: morning, midday, or afternoon. The goal is to find out if the time of day affects how well the drugs work and if they help improve survival. Participants will be monitored closely, and some may have optional tumor biopsies. After study treatment, follow-up continues every 3 months for a year, then up to 5 years.